Mitsubishi UFJ Trust & Banking Corp decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 3.2% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,233,839 shares of the company’s stock after selling 73,380 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned approximately 0.21% of Eli Lilly and worth $183,845,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. BlackRock Inc. increased its holdings in shares of Eli Lilly and by 2,628.5% in the first quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock worth $5,236,731,000 after buying an additional 59,978,664 shares during the period. Vanguard Group Inc. increased its holdings in shares of Eli Lilly and by 3.3% in the first quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock worth $5,769,694,000 after buying an additional 2,181,701 shares during the period. Winslow Capital Management LLC increased its holdings in shares of Eli Lilly and by 79.7% in the first quarter. Winslow Capital Management LLC now owns 3,875,968 shares of the company’s stock worth $326,008,000 after buying an additional 1,719,538 shares during the period. Harbour Capital Advisors LLC increased its holdings in shares of Eli Lilly and by 7,919.1% in the second quarter. Harbour Capital Advisors LLC now owns 1,705,338 shares of the company’s stock worth $20,721,000 after buying an additional 1,684,072 shares during the period. Finally, Renaissance Technologies LLC increased its holdings in shares of Eli Lilly and by 93.6% in the first quarter. Renaissance Technologies LLC now owns 2,980,400 shares of the company’s stock worth $250,681,000 after buying an additional 1,441,200 shares during the period. Institutional investors and hedge funds own 75.53% of the company’s stock.

In other news, major shareholder Lilly Endowment Inc sold 180,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the transaction, the insider now directly owns 123,865,804 shares of the company’s stock, valued at $10,040,562,072.24. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders have sold 990,000 shares of company stock worth $82,949,650. Corporate insiders own 0.20% of the company’s stock.

Shares of Eli Lilly and Company (NYSE LLY) opened at 87.23 on Friday. The firm’s 50-day moving average price is $84.38 and its 200 day moving average price is $82.29. The company has a market capitalization of $92.03 billion, a PE ratio of 37.75 and a beta of 0.34. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $89.09.

Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.06. The business had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period last year, the company posted $0.86 earnings per share. On average, equities analysts forecast that Eli Lilly and Company will post $4.16 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be given a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.38%. The ex-dividend date of this dividend is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio (DPR) is presently 90.04%.

Several research firms have recently commented on LLY. Barclays PLC lifted their price objective on Eli Lilly and from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Tuesday, July 4th. BMO Capital Markets reiterated a “sell” rating and issued a $73.00 price objective on shares of Eli Lilly and in a report on Friday, August 4th. Berenberg Bank reiterated a “buy” rating and issued a $100.00 price objective on shares of Eli Lilly and in a report on Thursday, July 27th. Jefferies Group LLC reiterated a “buy” rating and issued a $96.00 price objective (up previously from $93.00) on shares of Eli Lilly and in a report on Thursday, July 13th. Finally, Cowen and Company reiterated a “buy” rating and issued a $95.00 price objective on shares of Eli Lilly and in a report on Wednesday, October 4th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the stock. Eli Lilly and currently has a consensus rating of “Hold” and an average price target of $88.97.

COPYRIGHT VIOLATION WARNING: “Mitsubishi UFJ Trust & Banking Corp Lowers Holdings in Eli Lilly and Company (LLY)” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/22/mitsubishi-ufj-trust-banking-corp-lowers-holdings-in-eli-lilly-and-company-lly.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.